Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16175
Title: Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed?
Austin Authors: Ramchand, Sabashini K ;Lim, Elgene;Grossmann, Mathis 
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Deparment of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Cancer Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia
Issue Date: Nov-2016
metadata.dc.date: 2016-08-06
Publication information: Clinical Endocrinology 2016; 85(5): 689-693
Abstract: Adjuvant endocrine therapy provides oncological benefits in women with early oestrogen receptor positive breast cancer, but has adverse effects consequent to induced oestradiol deficiency. Bone loss is accelerated, predisposing to increased fracture risk. Metabolic effects include changes in lipid metabolism and body composition although effects on cardiovascular risk are still unclear. Women commencing endocrine therapy should be proactively counselled about and monitored for these and other therapy-related complications including arthralgia and vasomotor symptoms. We provide strategies for prevention and management of these adverse effects, based, where available, on randomised controlled trial evidence specific to breast cancer survivors receiving endocrine treatment.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16175
DOI: 10.1111/cen.13172
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27497423
Type: Journal Article
Subjects: Adverse effects
Aromatase inhibitors
Breast cancer
Tamoxifen
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Nov 27, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.